Related Experiment Video
Updated: Jun 27, 2026
09:29
Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
Lamotrigine-valproic acid combination therapy for medically refractory epilepsy
Jeremy J Moeller1, Susan R Rahey, R Mark Sadler
1Department of Medicine, Division of Neurology, Dalhousie University, Halifax, Nova Scotia, Canada.
Epilepsia
|December 5, 2008
Summary
Lamotrigine-valproic acid combination therapy is effective for medically refractory epilepsy. This treatment achieved seizure freedom in over 50% of patients, regardless of epilepsy type or demographics.
Area of Science:
- Neurology
- Pharmacology
- Epileptology
Background:
- Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
- Medically refractory epilepsy poses significant treatment challenges, often requiring combination therapies.
- Lamotrigine (LTG) and valproic acid (VPA) are established antiepileptic drugs.
Purpose of the Study:
- To evaluate the efficacy of combining lamotrigine (LTG) and valproic acid (VPA) in patients with medically refractory epilepsy.
- To assess the impact of LTG-VPA combination therapy on seizure frequency and patient outcomes.
Main Methods:
- Retrospective chart review of 35 patients with medically refractory epilepsy treated with LTG-VPA for at least 6 months.
- Analysis of patient demographics, epilepsy type, severity, and prior treatment failures.
- Stratification into seizure-free, improved (≥50% reduction in seizure frequency), and unimproved groups.
Main Results:
- 51.4% of patients achieved complete seizure freedom with LTG-VPA therapy.
- An additional 11.4% of patients showed improvement (≥50% seizure reduction).
- Treatment effectiveness was independent of epilepsy type, severity, or patient demographics.
Conclusions:
- LTG-VPA combination therapy is a viable option for patients with medically refractory epilepsy.
- This combination demonstrates significant efficacy in achieving seizure control.
- Consideration of LTG-VPA is warranted for refractory epilepsy cases unresponsive to other treatments.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...